Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In InVivo Therapeutics Holdings Corp. (NVIV) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InVivo Therapeutics Holdings Corp. (“InVivo” or the “Company”) (OTC: NVIV) of the October 6, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against InVivo and certain executives.
A complaint has been filed in the United States District Court of Massachusetts on behalf of all persons who purchased or acquired InVivo securities between April 5, 2013 through August 26, 2013, inclusive (the “Class Period”).
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that during the Class Period, the Company failed to disclose the timeframe within which its first-in-man clinical study for its biopolymer scaffolding product would be complete and data submitted to the United States Food and Drug Administration (“FDA”).
On August 27, 2013, the Company announced that it would need at least 24 months from the date of the first enrolled patient to complete clinical trials for its biopolymer scaffold product.
Following this news, the price of InVivo stock declined by $1.37, or roughly 40%, to close at $2.07 on August 27, 2014.
If you invested in InVivo stock or options between April 5, 2013 through August 26, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding InVivo’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.